Navigation Links
Appointment of Chief Executive Officer
Date:9/19/2011

erapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™ and DACC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment o
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. ADVENTRX Announces Appointment of Senior Vice President, Commercial
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
5. Access Legal Announces Appointment of Nicholas Tubb to Medical Negligence Team
6. OncoSec Announces Clinical Leadership Appointments
7. Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board
8. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
9. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
10. OncoSec Announces Leadership Team Appointments
11. ERT Announces Appointment of New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... (Aug. 18, 2014) -- A new therapy developed ... (USF) Morsani College of Medicine and Columbia University ... complications of interventional cardiovascular disease treatment. , ... the novel molecular therapy could selectively inhibit blood ... a medical procedure using a balloon catheter to ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
(Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... ROCKVILLE, Md., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ... financial,results in a press release to be issued after ... will hold an investor conference call to,discuss its financial ... The call will be hosted by Novavax President and ...
... Lead Cancer Stem Cell Product Candidate Enters Clinical ... OncoMed Pharmaceuticals, a,clinical-stage company developing novel antibody therapeutics ... completion of the final,tranche of its Series B ... total Series B financing to $154 million. New ...
... at Berlin conference, RALEIGH, N.C., Nov. 4 ... it will present during the,Partnerships in Clinical Trials ... PRA,s Christian Tucat, Senior Vice President of Business,Development ... evolution of CRO,partnerships?" at 4PM on Wednesday, 5 ...
Cached Biology Technology:Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2OncoMed Pharmaceuticals Completes Series B Financing 2OncoMed Pharmaceuticals Completes Series B Financing 3PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress 2
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
(Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
(Date:8/20/2014)... ROBERTS, Washington , August 20, 2014 ... Security Concerns in the Payment Industry?   ... sectors including biometrics, issues commentary from analysts and experts on ... , Managing Partner at Thrive Analytics, Isabelle Moeller ... of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Vision Australia (BVA) today unveils their wide-view neurostimulator concept ... Australia,s first recipient of the technology. The ... University of New South Wales and unveiled today at ... Melbourne, will deliver improved quality of life for patients ...
... helping fight a multi-front war on cancer may do the ... Cancer and cardiovascular disease, both among top U.S. killers, ... as a treatment could become additional common ground, said Dr. ... think hsp90 inhibitors may be some of the best anti-inflammatory ...
... March 30, 2010 Two new tuberculosis studies by ... bad news about the bacterium that infects nearly a ... kills nearly 2 million people each year. ... shows promise at overcoming some drug-resistant tuberculosis, at least ...
Cached Biology News:Bionic Vision Australia puts bionic eye in sight 2New cancer therapy may fight cardiovascular disease 2UT Southwestern researchers find clues to TB drug resistance 2UT Southwestern researchers find clues to TB drug resistance 3
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
... and miRNA Isolation Traditional mRNA isolation ... and can result in the loss of ... miRNA Isolation Kit purifies all RNA species ... Through an enrichment procedure included in the ...
Biology Products: